Company Overview
Neuronetics, Inc. operates within the healthcare sector, specifically focusing on the medical devices industry by offering in-office treatments for patients suffering from neurohealth disorders both domestically and internationally. The firm's primary offering is the NeuroStar Advanced Therapy System, which functions as a non-invasive, non-systemic, office-based solution designed to treat adult patients with major depressive disorders. This specialized business model positions the company as a provider of advanced therapeutic technology rather than a mass-market pharmaceutical entity. The entity currently maintains a market capitalization of $89.37M and generates an annualized trailing twelve-month revenue of $149.16M while employing a workforce of 658 individuals. These financial metrics indicate that the company operates with a relatively small market capitalization relative to its revenue generation, suggesting a micro-cap profile that often accompanies companies in specialized medical device niches where capital efficiency is prioritized over broad market penetration. The disparity between the $149.16M in revenue and the $89.37M market cap further highlights the market's cautious assessment of future earnings potential given the company's current profitability status.
Financial Health
The company reported a revenue of $149.16M over the trailing twelve months, yet this top-line activity resulted in a net income of $-38,998,000 and an EBITDA of $-27,631,000, revealing a significant gap between gross sales and bottom-line earnings that points to substantial operating expenses or one-time costs impacting the cost structure. This negative net income is exacerbated by a free cash flow of $-10,412,875, which indicates that the company is currently consuming cash rather than generating it, thereby limiting its financial flexibility for debt reduction or capital expenditures without external financing. Marginal analysis shows a gross margin of 48.7%, which is healthy for a medical device firm, but this is eroded by operating expenses to yield an operating margin of -11.1% and a profit margin of -26.1%, demonstrating that high fixed costs or sales commissions are consuming the majority of gross profits. The balance sheet presents a leveraged profile with total debt standing at $90.30M against total cash reserves of $28.13M, resulting in a debt-to-equity ratio of 344.14% which signifies a high level of financial leverage relative to shareholder equity. Despite the high debt load, the current ratio remains at 2.02, indicating that the company holds sufficient liquid assets to cover its short-term obligations more than twice over, suggesting a manageable immediate liquidity position. Return metrics reflect the financial strain with a return on equity of -134.9% and a return on assets of -13.7%, revealing that management effectiveness in generating returns on the capital base is currently negative across both equity and asset lines.
Valuation Assessment
Valuation multiples for Neuronetics, Inc. reflect its lack of profitability, as the P/E Ratio (TTM) is listed as N/A while the Forward P/E stands at -4.03, implying that the market anticipates earnings to remain negative or that the current earnings figure does not yet reflect future operational improvements. The price-to-book ratio is 3.98, which indicates that the stock is trading at a significant premium over its net asset value, suggesting investors are pricing in future growth potential or intangible assets that are not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 0.60 and an EV/EBITDA of -5.62 provide context for investors, showing that the company is valued at roughly 60% of its sales revenue despite burning cash, a common dynamic for growth-stage biotech or medtech firms awaiting regulatory approvals or product expansion. Price action data shows a 52-week high of $5.05 and a 52-week low of $0.80, meaning the current trading price sits significantly below the annual peak and reflects a wide trading range driven by market sentiment regarding the company's turnaround prospects. The beta value is 0.94, which indicates that the stock's price volatility is closely aligned with the broader market, moving in tandem with general market fluctuations rather than exhibiting extreme defensive or aggressive characteristics.
Growth & Income
Revenue growth is robust at 85.7% year-over-year, while earnings growth is listed as N/A due to the absence of positive earnings in the prior period, implying that top-line expansion is currently outpacing any potential earnings recovery or that earnings are simply not yet positive to measure growth rates. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means that all available earnings or cash flows are being retained within the business to fund operations, research, or debt repayment rather than being distributed to shareholders. Consequently, the income profile is non-existent in the current period, forcing reliance on capital appreciation or operational turnaround to generate shareholder value. The overall growth and income profile is characterized by high revenue expansion coupled with negative earnings and no dividend distribution, typical of a capital-intensive medical device company in a pre-profitability or recovery phase.